Boston back on the acquisition trail after reducing Guidant debt
This article was originally published in Clinica
Executive Summary
Boston Scientific is shopping for acquisitions outside its core business, after finally reducing the level of debt from its acquisition of Guidant to "comfortable" levels, according to interim CEO Hank Kucheman. He was speaking at the JP Morgan Conference, currently being held in San Francisco, California.